Recursion Pharmaceuticals, Inc. RXRX Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s other accrued liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported other accrued liabilities of $12.56M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s other accrued liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s other accrued liabilities increased by 12.0% year-over-year, from $11.21M to $12.56M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s other accrued liabilities?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s other accrued liabilities has grown at a 30.4% compound annual growth rate (CAGR), from $4.77M to $17.97M.